Alto Neuroscience Launches $93.9M Stock Offering at $26.48 in BofA-Led Underwriting
Complete. Here is the key summaryAlto Neuroscience launched a $93.9 million registered direct stock offering at $26.48 per share, led by BofA Securities. The company will issue 3,776,436 common shares, with proceeds allocated to accelerate clinical development of ALTO-207, including a Phase 3 trial, and for general working capital. The transaction is expected to close on July 14, 2026.
Alto Neuroscience entered into an underwriting agreement to sell 3,776,436 shares of common stock at $26.48 per share in a registered direct offering. The company expects approximately $93.9 million in net proceeds, with closing anticipated on Jul 14, 2026, subject to customary conditions. The BofA Securities-led syndicate includes Stifel, William Blair, and Baird as joint bookrunners, with JonesTrading and H.C. Wainwright as co-managers. Proceeds will support accelerated clinical development of ALTO-207, including an additional planned Phase 3 trial, and general working capital.
Agreement details:
- Agreement type: Underwriting agreement for registered direct common stock offering
- Counterparty: BofA Securities, as representative of the underwriters
- Signed / Effective: Jul 13 2026 / same
- Duration / Termination: At will
- Reason: Raise capital for ALTO-207 and working capital
Original SEC Filing: Alto Neuroscience, Inc. [ ANRO ] - 8-K - Jul. 14, 2026